References
- NoseworthyJHLucchinettiCRodriguezMWeinshenkerBGMultiple sclerosisN Engl J Med20003431393895211006371
- TullmanMJOverview of epidemiology, diagnosis, and disease progression associated with multiple sclerosisAm J Manag Care2013192 supplS15S2023544716
- RenouxCVukusicSMikaeloffYAdult Neurology Departments KIDMUS Study GroupNatural history of multiple sclerosis with childhood onsetN Engl J Med2007356252603261317582070
- SolaroCPonzioMMoranEThe changing face of multiple sclerosis: prevalence and incidence in an aging populationMult Scler Epub2015112
- LublinFDReingoldSCDefining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple SclerosisNeurology19964649079118780061
- FrischerJMBramowSDal-BiancoAThe relation between inflammation and neurodegeneration in multiple sclerosis brainsBrain200913251175118919339255
- TrojanoMPaolicelliDBellacosaACataldoSThe transition from relapsing-remitting MS to irreversible disability: clinical evaluationNeurol Sci200324suppl 5S268S27014652786
- GoodinDSRederATEbersGCSurvival in MS: a randomized cohort study 21 years after the start of the pivotal IFNB-1b trialNeurology201278171315132222496198
- RudickRAMillerDMHealth-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatmentCNS Drugs2008221082783918788835
- MikulaPNagyovaIKrokavcovaMSocial participation and health-related qualiy of life in people with multiple sclerosisDisabil Health J201581293425130596
- UccelliMMThe impact of multiple sclerosis on family members: a review of the literatureNeurodegener Dis Manag20144217718524832035
- SundströmPNystromLSvenningssonAFordgrenLSick leave and professional assistance for multiple sclerosis individuals in Väasterbotten County, Northern SwedenMult Scler20039551552014582779
- BaumstarckKPelletierJBoucekineMAuquierPMusiQoL study group. Predictors of quality of life in patiens with relapsing-remitting multiple sclerosis: A 2-year longitudinal studyRev Neurol (Paris)2015171217318025558798
- PutzkiNFischerJGottwaldK“Mensch im Mittelpunkt” Study GroupQuality of life in 1000 patients with early relapsing-remitting multiple sclerosisEur J Neurol200916671372019475754
- Fernendez-JimenezEArnettPAImpact of neurological impairment, depression, cognitive function and coping on quality of life in people with multiple sclerosis: a relative importance analysisMult Scler Epub20141222
- The IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology19934346556618469318
- JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease proression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol1996393898904
- PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multipl Sclerosis) Study GroupRandomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosisLancet19983529139149815049820297
- JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology1995457126812767617181
- SorensenPSNew management algorithms in multiple sclerosisCurr Opin Neurol201427324625924759080
- SormaniMPRioJTintorèMScoring treatment response in patients with relapsing multiple sclerosisMult Scler201219560561223012253
- PolmanCHO’ConnorCWHavrdovaEAFFIRM InvestigatorsA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
- RudickRAStuartWHCalabresiPASENTINEL InvestigatorsNatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med2006354991192316510745
- HavrdovaEGalettaSHutchinsonMEffect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) trialLancet Neurol20098325426019201654
- HavrdovaEGalettaSStefoskiDComiGFreedom from disease activity in multiple sclerosisNeurology201074suppl 3S3S720421571
- Langer-GouldAAtlasSWGreenAJBollenAWPelletierDProgressive multifocal leukoencephalopathy in a patient treated with natalizumabN Engl J Med2005353437538115947078
- Kleinschmidt-DeMastersBKTylerKLProgressive multifocal leuko-encephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosisN Engl J Med2005353436937415947079
- Van AsscheGVan RanstMSciotRProgressive multifocal leucoencephalopathy after natalizumab therapy for Crohn’s diseaseN Engl J Med2005353436236815947080
- KapposLRadueEWO’ConnorPFREEDOMS Study GroupA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740220089952
- CohenJABarkhofFComiGTRANSFORMS Study GroupOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
- FoxRJMillerDHPhillipsJTCONFIRM Study InvestigatorsCONFIRM Study Investigators. Placebo-controlled phase III study of oral BG-12 or glatiramer acetate in multiple sclerosisN Engl J Med2012367121087109722992072
- GoldRKapposLArnoldDLDEFINE Study InvestigatorsDEFINE Study Investigators. Placebo-controlled phase III study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
- O’ConnorPWolinskyJSConfavreuxCTEMSO Trial GroupRandomized trial of oral teriflunomide in relapsing multiple sclerosisN Engl J Med2011365141293130321991951
- ConfavreuxCO’ConnorPComiGTOWER Trial GroupOral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled trialLancet201413324725624461574
- CohenJAColesAJArnoldDLCARE-MS I InvestigatorsAlemtuzumab versus interferon beta-1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialLancet201238098561819182823122652
- ColesAJTwymanCLArnoldDLCARE-MS II InvestigatorsCARE-MS II investigatorsLancet201238098561829183923122650
- BielekovaBBeckerBLMonoclonal antibodies in MS: mechanisms of actionNeurology201074suppl 1S31S4020038761
- YednockTACannonCFritzLCSanchez-MadridFSteinmanLKarinNPrevention of experimental autoimmune encephalomyelitis by antibodies against alpha1beta integrinNature1992356636463661538783
- TubridyNBehanPOCapildeoRThe effect of anti-alpha4 integrin antibody on brain lesion activity in MSNeurology19993346647210449105
- GoodmanADRossmanHBar-OrAGLANCE InvestigatorsGLANCE: results of a phase 2, randomized, double-blind, placebo-controlled studyNeurology200972980681219255407
- WoodBvan der MeiIPonsonbyALPrevalence and occurence of anxiety, depression and fatigue over time in multiple sclerosisMult Scler201219221722422729988
- BakshiRShaikhZAMiletichRSFatigue in multiple sclerosis and its relationship to depression and neurologic disabilityMult Scler20006318118510871830
- BergamaschiRRomaniAVersinoMPoliRCosiVClinical aspects of fatigue in multiple sclerosisFunct Neurol19971252472519439942
- SvenningssonAFalkECeliusEGTynergy Trial InvestigatorsNatalizumab reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life settingPLoS One201383e5864323555589
- IaffaldanoPViterboRGPaolicelliDImpact of natalizumab on cognitive performance and fatigue in relapsing multiple sclerosis: a prospective, open-label, two-year observational studyPLoS One20127435843
- WickströmANyströmJSvenningssonAImproved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatmentMult Scler201319562263023012254
- RudickRAMillerDHassSAFFIRM and SENTINEL InvestigatorsHealth-related quality of life in multiple sclerosis: effects of natalizumabAnn Neurol200762433534617696126
- O’ConnorPGoodmanAKapposLLong-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS studyNeurology2014831788624898925
- ButzkuevenHKapposLPellegriniFTYSABRI Observational Program (TOP) InvestigatorsEfficacy and safety of natalizumab in multiple sclerosis: interim observataional programme resultsJ Neurol Neurosurg Psychiatry201485111190119724532785
- FerenczyMWMarshallLJNelsonCDMolecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC-virus induced demyelinating disease of the human brainClin Microbiol Rev201225347150622763635
- BloomgrenGRichmanSHotermansCRisk of natalizumab-associated progressive multifocal leukoencephalopathyN Engl J Med2012366201870188022591293
- Biogen IdecBiogen Idec Medinfo2015 Available from: http://www.Tysabri.comAccessed January, 2015
- WattjesMPBarkhofFDiagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRICurr Opin Neurol201427326027024739400
- FineAJSorbelloACortepeterCScarazziniLProgressive multifocal leukoencephalopathy after natalizumab discontinuationAnn Neurol201475110811524242357
- DahlhausSHoepnerRChanADisease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopthy patientsJ Neurol Neurosurg Psychiatry201384101068107423606731
- WenningWHaghikiaALaubenbergerJTreatment of progressive multifocal leukoencephalopathy associated with natalizumabN Engl J Med2009361111075108019741228
- CliffordDBDe LucaASimpsonDMArendtGGiovannoniGNathANatalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesLancet Neurol20109443844620298967
- VermerschPKapposLGoldRClinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyNeurology201176201607170421536645
- Dong-SiTRichmanSWattjesMPOutcome and survival of asymptomatic PML in natalizumab-treated MS patientsAnn Clin Transl Neurol201411075576425493267
- RothwellPMMcDowellZWongCKDormanPJDoctors and patients don’t agree: cross sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosisBMJ19973147094158015839169401
- HeesenCKleiterINguyenFRisk perception in natalizumab-treated patients and their neurologistsMult Scler201016121507151220826527
- O’ConnorPWGoodmanAKapposLDisease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology201176221858186521543733
- LassmannHBrückWLucchinettiCFThe immunopathology of multiple sclerosis: an overview [review]Brain Pathol200717221021817388952
- SormaniMPBruzziPCan we measure long-term treatment effects in multiple sclerosis? [review]Nat Rev Neurol201511317618225534913
- ScalfariANeuhausADegenhardtAThe natural history of multiple sclerosis, a geographically based study. 10. Relapses and long-term disabilityBrain201013371914192920534650
- FisnikuLKBrexPAAltmannDRDisability and T2 MRI lesions: a 20-year follow-up of patients with relapse-onset of multiple sclerosisBrain2008131380881718234696
- SimonJHKinkelRPKollmanCCHAMPIONS Investigators GroupTen-year follow-up of the “minimal MRI lesion” subgroup from the original CHAMPS multiple sclerosis prevention trialMult Scler201521441542225344370
- TrappBDRansahoffRRudickRAAxonal pathology in multiple sclerosis: relationship to neurologic disability [review]Curr Opin Neurol199912329530210499174
- European Medicine Agency (EMA)Product Information Tysabri2014 Available from: http://www.ema.europa.euAccessed December, 2014
- US Food and Drug Administration (FDA)Product Information Tysabri2014 Available from: http://www.FDA.govAccessed December, 2014
- PlavinaTSubramanyamMBloomgrenGAnti-JC-virus antibody levels in derum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathyAnn Neurol201476680281225273271
- AntoniolCStankoffBImmunological markers for PML prediction in MS patients treated with natalizumabFront Immunol2015566825601865
- CutterGRStüveODoes risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?Mult Scler201420101304130524812045
- OlssonTAchironAAlfredssonLAnti-JC virus antibody prevalence in a multinational multiple sclerosis cohortMult Scler201319111533153823459571
- LeePPlavinaTCastroAA second generation ELISA (STRATIFY JCVTM Dx Select TM) for detection of JC virus antibodies in human serum and plasma to support prorgessice multifocal leukoencephalopathy risk stratificationJ Clin Virol201357214114623465394
- OutteryckOZéphirHSalleronJJC-virus seroconversion in multiple sclerosis patients receiving natalizumabMult Scler2014207822829
- TurCMontalbanXNatalizumab: risk stratification of individual patients with multiple sclerosisCNS Drugs201428764164824942634
- European Medicine Agency (EMA)Product Information Gilenya2015 Available from: http://www.ema.europa.euAccessed January 27, 2015
- US Food and Drug Administration (FDA)Product Information Gilenya2015 Available from: http://www.fda.govAccessed January 27, 2015
- KalincikTHorakovaDSpelmanTMSBase Study GroupSwitch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisAnn Neurol201577342543525546031
- CarruthersRLRotsteinDLHealyBCChitnisTWeinerHLBuckleGJAn observational comparison of natalizumab versus fingolimod usind JCV serology to determine therapyMult Scler201420101381139024852928
- RosenstielPVGottschalkRCappielloLZhangYSaidMKapposLLong-term safety of fingolimod: interim evaluation of data from the longterms trialMult Scler Relat Disord20143675225891590
- European Medicine Agency (EMA)Product Information Lemtrada2015 Available from: http://www.ema.europa.euAccessed January 27, 2015
- US Food and Drug Administration (FDA)Lemtrada (Alemtuzumab)2015 Available from: http://www.fda.orgAccessed March 31, 2015
- FilippiniGDel GiovaneCVacchiLImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisCochrane Database Syst Rev20136CD00893323744561
- CukerAColesAJSullivanHA distinctive form of immune thrombocytopenis in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosisBlood2011118246299630521960587
- GormanMHealyBPolgar-TurcsanyiMChitnisTIncreased relapse-rate in pediatric-onset compared to adult-onset multiple sclerosisArch Neurol2009661545919139299
- YehEAWaubantEKruppLBNetwork of Pediatric MS Centers of ExcellenceMultiple sclerosis therapies in pediatric patients with refractory diseaseArch Neurol201168443744421149803
- KornekBAboul-EneinFRostasyKNatalizumab therapy for highly active multiple sclerosisJAMA Neurol201370446947523420110
- GhezziAPozzilliCGrimaldiLMItalian MS Study GroupNatalizumab in pediatric multiple sclerosis: results of a cohort of 55 casesMult Scler20131981106111223401129
- TrampeAKHemmelmannCStroetAAnti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohortNeurology201278221736174222592369
- MenzinJCaonCNicholsCWhiteLAFriedmanMPillMWNarrative review on the literature on adherence to disease-modifying therapies among patients with multiple sclerosisJ Manag Care Pharm2013101 suppl AS24S4023383731
- HalpernRAgarwalSBortonLOneacreKLopez-BresnahanMVAdherence and persistence among multiple sclerosis patients after one immunomodulatory failure: retrospective claims analysisAdv Ther201128976177521870169
- BergvallNPetrillaAAKarkareSUPersistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US database claims analysisJ Med Econ2014171069670725019581
- GlanzBIMusallamARintellDJTreatment satisfaction in multiple sclerosisInt J MS Care2014162687525061430
- BorrielloGProsperiniLMancinelliCGiannìCFubelliFPozzilliCPulse monthly steroids during an elective interruption of natalizumab: a post-marketing studyEur J Neurol201219578387822054236
- WestTWCreeBANatalizumab dosage suspension: are we helping or hurting?Ann Neurol201068339539920818793
- RossiSMottaCStuderVEffect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumabEur J Neurol2013201879422741530
- StüveOCravensPDFrohmanEMImmunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyNeurology200972539640118987352
- FoxRJCreeBACDe SèzeJMS disease activity in RESTORE: a randomized 24-week natalizumab interruption studyNeurology201482171491149824682966
- ClericoMSchiavettiIDe MercantiSFTreatment of relapsing remitting multiple sclerosis after 24 doses of natalizumab. Evidence from an Italian spontaneous, prospective, and observational study (TY-STOP Study)JAMA Neurol201471895496024977406
- HavlaJTackenbergBHellwigKFingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosisJ Neurol201326051382138723266894
- LaroniABrogiDMilesiVAbateLUccelliVMancardiGEarly switch to fingolimod may decrease the risk to disease recurrence after natalizumab interruptionMult Scler20131991236123723184503
- CentonzeDRossiSRinaldiFGalloPSevere relapses under fingolimod treatment prescribed after natalizumabNeurology201279192004200523035063
- SempereAPMartín-MedinaPBerenguer-RuizLSwitiching from natalizumab to fingolimod: an observational studyActa Neurol Scand2013128e6e1023336398
- JokubaitisVGLiVKalincikTMSBase Study GroupFingolimod after natalizumab and the risk of short-term relapseNeurology2014821204121124610329
- KapposLDisease control and safety in relapsing-remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32 week, rater- and patient blind, randomized, parallel-group study (TOFINGO)Mult Scler201319S150 Oral presentation 167
- GiovannoniGNaismithRTNatalizumab to fingolimod washout in patients at risk for PML: when good intentions yield bad outcomesNeurology201482141196119724610331
- FDAFDA Drug Safety Communication: FDA Warns About Case of Rare Brain Infection PML with MS Drug Tecfidera2014 Available from: www.fda.gov/Drugs/DrugSafety/ucm424625.htmAccessed January 25, 2015
- ErmisUWiesmannMNolteKFumaric acid-associated progressive multifocal leukencephalopathy (PML), treatment and survival in a patient with psoriasisKongress der Deutschen Gesellschaft für Neurologie2011143040
- van OostenBWKilllesteinJBarkhofFPolmanCHWattjesMPPML in a patient treated with dimethyl fumarate from a compounding pharmacyN Engl J Med2013368171659166123614605